Detalhe da pesquisa
1.
Clinical and economic burden of physician-diagnosed influenza in adults during the 2017/2018 epidemic season in Spain.
BMC Public Health
; 22(1): 2369, 2022 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36527015
2.
Healthcare resource use and associated costs in a cohort of hospitalized COVID-19 patients in Spain: A retrospective analysis from the first to the third pandemic wave. EPICOV study.
PLoS One
; 18(1): e0280940, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36696406
3.
Cost-utility analysis of influenza vaccination in a population aged 65 years or older in Spain with a high-dose vaccine versus an adjuvanted vaccine.
Vaccine
; 39(36): 5138-5145, 2021 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34344553
4.
Health care professionals' preference for a fully liquid, ready-to-use hexavalent vaccine in Spain.
Prev Med Rep
; 22: 101376, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33996389
5.
From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain.
PLoS One
; 15(5): e0233526, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32437476
6.
The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older.
J Med Econ
; 19(6): 576-86, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26808422
7.
Cost-effectiveness analysis has to consider all available evidence when informing inputs.
Hum Vaccin Immunother
; 17(3): 694-695, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961079
8.
Economic and psychosocial impact of rotavirus infection in Spain: a literature review.
Vaccine
; 32(30): 3740-51, 2014 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-24837768